Retraction Note to: Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19 (2021)

Peer-Reviewed Study · Jin C, Yu B, Zhang J, Wu H, Zhou X, Yao H, Liu F, Lu X, Cheng L, Jiang M, Wu N · July 9, 2021

Jin C et al., 2021-07-09: The retraction notice for the Chinese plasma-inactivation study the BluZone documents rely on for the 'eliminated within 2 minutes' figure. The notice retracts the article and gives the grounds: image overlap in Fig. 1 and undisclosed competing interests involving Boxin and the BX-1 device.

Retraction Note to: Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19.

Jin C et al., 2021-07-09: The retraction notice for the Chinese plasma-inactivation study the BluZone documents rely on for the 'eliminated within 2 minutes' figure. The notice retracts the article and gives the grounds: image overlap in Fig. 1 and undisclosed competing interests involving Boxin and the BX-1 device. Record field / notice title transcribed. The retracted article: BMC Infect Dis 2021;21:357, doi 10.1186/s12879-021-05993-0, received 2020 and published April 2021 – not, as the BluZone documents state, a 'March 2020' study. Retraction notice: BMC Infect Dis 2021;21:672. Study details from the retracted abstract: MB 1-4 uM in plasma, 630 nm light, 55,000 lux, BX-1 'AIDS treatment instrument'; virus load measured by RT-PCR. Funders/authors include Boxin (Beijing) Biotechnology, which made the device. Study type: other.